Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of the study is to evaluate the safety and tolerability of flexible doses of Extended Release (ER) OROS® paliperidone (3 to 12 mg/day) as compared with placebo in subjects with schizophrenia who are 65 years of age or older. The primary objective of the open-label extension is the long-term assessment of safety and tolerability of ER OROS paliperidone (3 to 12 mg/day) in subjects diagnosed with schizophrenia.
Critère d'inclusion
- Schizophrenia